Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.81 |
| ▸ | CNR2 | P34972 | 10/20 | 0.81 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.49 |
| ▸ | MLNR | O43193 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | CCKAR | P32238 | 1/20 | 0.49 |
| ▸ | CCKBR | P32239 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023856 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL1748614 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL5444990 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL29375695 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL8452745 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL2018977 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL4608199 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL2419758 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| SCHEMBL8470688 | 1.00 | CNR1 (0.81) | CNR1CNR2ABCC4MLNRABCB11 | |
| Hydrochloric Acid SCHEMBL4551016 | 0.99 | CNR1 (0.80) | CNR1CNR2ABCC4MLNRABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9662320-B2 | Antagonists of the cannabinoid receptor CB1 for use in the treatment of diseases associated with neuronal dendritic abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2017-05-30 | — | — | US | claimed |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | UNIVERSITAT POMPEU FABRA (ES) | 2016-03-10 | — | — | US | claimed |
| EP-1626963-B1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE LABOR DR (ES) | 2012-08-15 | — | — | EP | claimed |
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| US-7745476-B2 | 1,3,5-trisubstituted 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity | SOLVAY PHARMACEUTICALS B.V. (NL) | 2010-06-29 | — | — | US | claimed |
| US-7524868-B2 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-04-28 | — | — | US | claimed |
| EP-2042175-A1 | Dose regimens of CB1-Receptor ligands in the treatment of obesity | Laboratorios del Dr. Esteve S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| EP-2026798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CBX CANNABINOID RECEPTOR MODULATORS AND POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-02-25 | — | — | EP | claimed |
| EP-2012775-A1 | USE OF CBX CANNABINOID RECEPTOR MODULATORS AS POTASSIUM CHANNEL MODULATORS | Solvay Pharmaceuticals GmbH (DE) | 2009-01-14 | — | — | EP | claimed |
| EP-1743639-A1 | Use of substituted pyrazoline compounds for the treatment of coagulation related diseases | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743641-A1 | Use of substituted pyrazoline compounds for the treatment of food disorders, including obesity or metabolic syndrome in patients with developed diabetes | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1743643-A1 | New formulations of substituted pyrazoline compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-17 | — | — | EP | claimed |
| EP-1718619-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | Laboratorios del Dr. Esteve S.A. (ES) | 2006-11-08 | — | — | EP | claimed |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DR. ESTEVE S.A. (ES) | 2006-08-24 | — | — | US | claimed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-1637522-A1 | Substituted pyrazoline compounds for reducing triglycerides in blood | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-22 | — | — | EP | claimed |
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2006-01-26 | — | — | US | claimed |
| WO-2005077909-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DR. ESTEVE S.A. (ES) | 2005-08-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020010-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885ABCC4 343/4885 |
| US-20060189658-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | PIR, SYMPK, P2RX5 | CNR1 990/4885CNR2 748/4885ABCC4 343/4885 |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | CNR1 1/4885CNR2 2/4885ABCC4 127/4885 |
| US-20160067235-A1 | Antagonists of the Cannabinoid Receptor CB1 for Use in the Treatment of Diseases Associated with Neuronal Dendritic Abnormalities | CNR1, CNR2, DBN1 | CNR1 1/4885CNR2 2/4885ABCC4 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.